Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis.
作者信息
Van Zee Art, Fiellin David A
机构信息
Art Van Zee is with the St. Charles Clinic, Stone Mountain Health Services, St. Charles, VA. David Fiellin is with the Departments of Medicine and Emergency Medicine and the Program in Addiction Medicine, Yale University School of Medicine, and the Department of Health Policy and Management and the Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT.
出版信息
Am J Public Health. 2019 Mar;109(3):393-394. doi: 10.2105/AJPH.2018.304899.
Abstract
摘要
相似文献
1
Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis.仅提供丁丙诺啡治疗的诊所激增：对国家应对阿片类药物危机的威胁。
Am J Public Health. 2019 Mar;109(3):393-394. doi: 10.2105/AJPH.2018.304899.
2
Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.美国阿片类药物泛滥背景下药物滥用治疗提供者的反应：2007-2016 年，按地理位置、运营和支付特征划分的丁丙诺啡和美沙酮治疗的差异。
PLoS One. 2020 Mar 3;15(3):e0229787. doi: 10.1371/journal.pone.0229787. eCollection 2020.
3
Out-of-Pocket Costs and Payer Types for Buprenorphine Among US Youth Aged 12 to 19 Years.美国12至19岁青少年丁丙诺啡的自付费用和支付方类型
JAMA Pediatr. 2023 Oct 1;177(10):1096-1098. doi: 10.1001/jamapediatrics.2023.2376.
4
Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.阿片类药物依赖患者的管理：丁丙诺啡/纳洛酮或美沙酮使用相关成本的比较，以及它们与感染性或精神性合并症的伴随治疗之间的相互作用。
Adicciones. 2015 Sep 15;27(3):179-89.
5
Public policy statement on buprenorphine for opiate dependence and withdrawal.关于丁丙诺啡用于阿片类药物依赖及戒断的公共政策声明。
J Addict Dis. 2004;23(4):116-7.
6
Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.与使用丁丙诺啡-纳洛酮相关的阿片类药物使用情况及成本结果，这些使用情况及成本结果来自有处方阿片类药物使用史的患者。
J Manag Care Pharm. 2008 Mar;14(2):186-94. doi: 10.18553/jmcp.2008.14.2.186.
7
Changes in For-Profit Medication-Assisted Therapy Clinics in an Appalachian City.阿巴拉契亚城市营利性药物辅助治疗诊所的变化。
South Med J. 2021 Feb;114(2):70-72. doi: 10.14423/SMJ.0000000000001209.
8
Buprenorphine Maintenance vs. Placebo for Opioid Dependence.丁丙诺啡维持治疗与安慰剂治疗阿片类物质依赖的比较
Am Fam Physician. 2017 Mar 1;95(5):Online.
9
Association Between Cost-Sharing and Buprenorphine Prescription Abandonment.费用分担与丁丙诺啡处方放弃的关联。
J Gen Intern Med. 2024 Sep;39(12):2160-2168. doi: 10.1007/s11606-024-08819-2. Epub 2024 Jun 18.
10
New pharmacological tool approved for opioid addiction.用于阿片类药物成瘾的新型药理学工具获批。
HIV Clin. 2004 Summer;16(3):9-11.
引用本文的文献
1
Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl.非法芬太尼时代高剂量丁丙诺啡处方特征的横断面研究。
Addict Sci Clin Pract. 2025 Apr 9;20(1):33. doi: 10.1186/s13722-025-00547-0.
2
Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims.治疗环境和丁丙诺啡停药：多州保险索赔分析。
Addict Sci Clin Pract. 2024 Mar 16;19(1):17. doi: 10.1186/s13722-024-00450-0.
3
Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.基于办公室的医疗补助参保者成瘾治疗模式的实施：一项混合方法研究。
J Subst Use Addict Treat. 2024 Jan;156:209212. doi: 10.1016/j.josat.2023.209212. Epub 2023 Nov 5.
4
Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.在 2 个州的医疗补助计划中取消了治疗阿片类药物使用障碍的事先授权政策后，丁丙诺啡使用趋势。
JAMA Health Forum. 2022 Jun 24;3(6):e221757. doi: 10.1001/jamahealthforum.2022.1757. eCollection 2022 Jun.
5
A bifurcated opioid treatment system and widening insidious disparities.一种二元化的阿片类药物治疗体系与日益扩大的潜在差异。
Addict Behav. 2022 Jul;130:107296. doi: 10.1016/j.addbeh.2022.107296. Epub 2022 Mar 2.
6
The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.医疗补助扩张对美国各州使用丁丙诺啡治疗阿片类药物使用障碍的影响。
Drug Alcohol Depend. 2022 Mar 1;232:109336. doi: 10.1016/j.drugalcdep.2022.109336. Epub 2022 Jan 29.
7
Opiate and Cerebral Atrophy.阿片类药物与脑萎缩
Indian J Crit Care Med. 2020 Apr;24(4):218-219. doi: 10.5005/jp-journals-10071-23402.
8
Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?在医疗实践中开具丁丙诺啡治疗阿片类药物使用障碍：基于诊室的门诊治疗能否解决美国的阿片类药物危机？
Addiction. 2019 Nov;114(11):1992-1999. doi: 10.1111/add.14733. Epub 2019 Jul 25.
本文引用的文献
1
Access to and Payment for Office-Based Buprenorphine Treatment in Ohio.俄亥俄州基于办公室的丁丙诺啡治疗的获取与支付
Subst Abuse. 2017 Jun 13;11:1178221817699247. doi: 10.1177/1178221817699247. eCollection 2017.
2
Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population.多州人群中丁丙诺啡-纳洛酮治疗阿片类物质使用障碍的模式
Med Care. 2017 Jul;55(7):669-676. doi: 10.1097/MLR.0000000000000727.
3
Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013.2003 - 2013年美国门诊医生使用丁丙诺啡的趋势。
Am J Addict. 2015 Jan;24(1):24-9. doi: 10.1111/ajad.12174.
4
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.丁丙诺啡维持治疗与安慰剂或美沙酮维持治疗用于阿片类物质依赖的比较
Cochrane Database Syst Rev. 2014 Feb 6;2014(2):CD002207. doi: 10.1002/14651858.CD002207.pub4.
5
Acceptance of insurance by psychiatrists and the implications for access to mental health care.精神科医生对保险的接受及其对获得精神卫生保健的影响。
JAMA Psychiatry. 2014 Feb;71(2):176-81. doi: 10.1001/jamapsychiatry.2013.2862.
6
Reimbursement and practice policies among providers of buprenorphine-naloxone treatment.丁丙诺啡-纳洛酮治疗提供者的报销和实践政策。
Subst Abus. 2013;34(2):105-7. doi: 10.1080/08897077.2012.677753.
7
Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.无法获得丁丙诺啡治疗作为使用被转移丁丙诺啡的风险因素。
Drug Alcohol Depend. 2012 Dec 1;126(3):379-83. doi: 10.1016/j.drugalcdep.2012.05.025. Epub 2012 Jun 15.
Zotero 插件